"Mycobacterium avium complex" from_date:2012

Mycobacterium avium complex Skip to main contentSkip to searchEnglish (US)EnglishPortuguês中文Log inSearchSearchHomeMycobacterium avium complex MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:28 May 2024Last updated:26 Jun 2024Summary Mycobacterium avium complex (MAC) has variable presenting features including chronic cough, weight loss, and fevers. Increased incidence

Amikacin liposomal (Arikayce) - for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All

Opportunistic Infection Therapeutic Guidelines - Mycobacterium avium complex (MAC) VERSION 16.03.2023THERAPEUTIC GUIDELINES FOR OPPORTUNISTIC INFECTIONS MYCOBACTERIUM AVIUM COMPLEX (MAC)INITIAL RELEASE: MAY 2009LAST UPDATED: MARCH 2023BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV/AIDS PrEP GUIDELINES 2BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV/AIDSTHERAPEUTIC GUIDELINES FOR OPPORTUNISTIC therapy; AZM, azithromycin; CLA, clarithromycin; EMB, ethambutol; MAC, Mycobacterium avium complex; MAC-IRIS, Mycobacterium avium complex immune reconstitution inflammatory syndrome; DMAC, disseminated Mycobacterium avium complex; HAART, highly active an-tiretroviral therapy; NSAID, non-steroidal anti-inflammatory drug; PLWH, persons living with HIV; RCT, randomized controlled trial; RFB

Clinical commissioning policy: Nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex refractory to current treatment options (adults and post pubescent children) Skip to main contentHome News Publications Statistics Blogs Events Contact usSearch SearchAbout us Our work Commissioning Get involved CoronavirusClinical commissioning policy: Nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex refractory to current treatment options (adults and post pubescent children)Document first published:21 October 2022Page updated:21 October 2022Topic:Specialised commissioningPublication type:Policy or strategyNebulised liposomal amikacin

Amikacin (Arikayce) - Non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) 1 Published 13 September 2021 1 SMC2369 amikacin liposomal nebuliser dispersion 590mg (Arikayce®) Insmed Limited 6 August 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under the orphan medicine process amikacin liposomal nebuliser dispersion (Arikayce®) is not recommended for use within NHSScotland. Indication under review: Treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults

Challenges in achieving the guideline-recommended amikacin level for Mycobacterium avium complex pulmonary disease. The addition of aminoglycosides to a macrolide-based regimen is recommended for refractory complex pulmonary disease (MAC-PD). For intravenous amikacin (AMK) administration three times a week, the ATS/ERS/ESCMID/IDSA guidelines recommend targeting a peak serum concentration of 65

Intestinal obstruction caused by disseminated mycobacterium avium complex disease following solid organ transplantation: a case report. Mycobacterium avium complex (MAC) is a common pathogen causing non-tuberculous mycobacterial infections, primarily affecting the lungs. Disseminated MAC disease occurs mainly in immunocompromised individuals, such as those with acquired immunodeficiency syndrome

Comprehensive Management Algorithm for Mycobacterium avium Complex Pulmonary Disease in the Real-World Setting. The management of Mycobacterium avium complex pulmonary disease (MAC-PD) is challenging due to limited efficacy and frequent adverse events associated with standard treatments. The 2020 guidelines from ATS, ERS, ESCMID, and IDSA provide recommendations, but real-world adherence is often

Tolerability and efficacy of Mycobacterium avium complex pulmonary disease treatment in elderly patients. Mycobacterium avium complex pulmonary disease (MAC-PD) is considered to be increasing worldwide. In Japan, the number of elderly MAC-PD patients requiring treatment is also expected to increase due to the aging society. However, reduced organ function in elderly patients makes it often

Intermittent versus Daily Therapy for Noncavitary Mycobacterium avium Complex Pulmonary Disease: An Open-label Randomized Trial. : Patients with noncavitary nodular bronchiectatic (NB) complex pulmonary disease (MAC-PD) are treated intermittently three times a week, although no randomized controlled trials have been conducted comparing three times weekly to daily therapy. : To assess

A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against Mycobacterium avium complex subspecies in patients with active Crohn's disease. Crohn's Disease (CD) is a chronic, debilitating condition hypothesised to be associated with Mycobacterium avium ssp paratuberculosis (MAP) infection. It is the causative

A marmoset model for Mycobacterium avium complex pulmonary disease. Mycobacterium avium complex, is the most common nontuberculous mycobacterial respiratory pathogen in humans. Disease mechanisms are poorly understood due to the absence of a reliable animal model for M. avium complex pulmonary disease. The objectives of this study were to assess the susceptibility, immunologic

Phenotypic drug-susceptibility profiles and genetic analysis based on whole-genome sequencing of Mycobacterium avium complex isolates in Thailand. Mycobacterium avium complex (MAC) infections are a significant clinical challenge. Determining drug-susceptibility profiles and the genetic basis of drug resistance is crucial for guiding effective treatment strategies. This study aimed to determine

Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study. CONVERT, a randomized, active-controlled, global, Phase 3 trial demonstrated that patients with treatment-refractory Mycobacterium avium complex (MAC) pulmonary disease were more likely to achieve culture conversion

Mavintramycin A is a promising antibiotic for treating Mycobacterium avium complex infectious disease. complex (MAC) is a serious disease that is mainly caused by infection with the non-tuberculous mycobacteria (NTM), and . Seven new compounds, designated mavintramycins A-G (-), were isolated along with structurally related compounds, including amicetin () and plicacetin (), from the culture

The Impact of Trehalose Dimycolate on the Clinical Course of Mycobacterium avium Complex Pulmonary Disease. Rationale The clinical implications of trehalose 6,6'-dimycolate (TDM) in nontuberculous mycobacterial pulmonary disease have not been studied. Objective To examine the presence of TDM in clinical isolates obtained from patients with Mycobacterium avium complex (MAC) pulmonary disease (PD

Clinical and genomic features of Mycobacterium avium complex: a multi-national European study. The Mycobacterium avium complex (MAC) comprises the most frequent non-tuberculous mycobacteria (NTM) in Central Europe and currently includes twelve species. M. avium (MAV), M. intracellulare subsp. intracellulare (MINT), and M. intracellulare subsp. chimaera (MCH) are clinically most relevant. However

Serum Cell-free DNA-based Detection of Mycobacterium Avium Complex Infection. complex (MAC) is the most common cause of nontuberculous mycobacterial pulmonary disease (NTM-PD), which exhibits increasing global incidence. Current microbiologic methods routinely used in clinical practice lack sensitivity and have long latencies, leading to delays in diagnosis and treatment initiation

"How do I manage disseminated Mycobacterium avium complex (MAC) disease in people with HIV?". Advanced HIV disease (AHD) is increasing, with late presentation accounting for half of newly diagnosed people with HIV (PWH) in Europe. Mortality in late-presenting PWH remains high, and Mycobacterium avium complex (MAC) disease, among other opportunistic infections, presents several diagnostic

Phenotypic amikacin resistance may not indicate poor response to amikacin in Mycobacterium avium complex pulmonary disease. When using amikacin to treat complex pulmonary disease (MAC-PD), a minimum inhibitory concentration resistance breakpoint of ≥64 mcg/mL is recommended. We explored whether amikacin resistance characterized by phenotypic drug susceptibility testing was associated